NOVO-B vs NVO: Side-by-Side Comparison
Compare Novo Nordisk A/S (NOVO-B) and Novo Nordisk (NVO) side by side: market cap DKK 1.39T vs USD 223.40B, P/E 11.5 vs 11.8. Financials, growth and model signals on Bullrun.
| Metric | NOVO-B | NVO |
|---|---|---|
| Company | Novo Nordisk A/S | Novo Nordisk |
| Country / Exchange | Denmark · CO | Denmark · NYSE |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers-General |
| Market cap | DKK 1.39T | USD 223.40B |
| P/E ratio | 11.5 | 11.8 |
| Dividend yield | 5.00% | 2.53% |
| Valuation model | 21.7% undervalued | 23.4% undervalued |
| Revenue (latest FY) | DKK 309.06B | — |
| Revenue growth YoY | +6.4% | — |
| Net income | DKK 102.43B | — |
| Gross margin | 81.0% | — |
| Diluted EPS | 23.03 | — |